Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 7/20 | 1.00 |
| ▸ | SMARCA4 | P51532 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 0.70 |
| ▸ | RAB9A | P51151 | 8/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9599834 | 0.86 | SMARCA2 (0.86) | SMARCA2SMARCA4NPC1RAB9AMEN1 | |
| SCHEMBL119685 | 0.84 | SMARCA2 (0.79) | SMARCA2SMARCA4NPC1RAB9AMEN1 | |
| SCHEMBL22125141 | 0.84 | SMARCA2 (0.72) | SMARCA2SMARCA4NPC1RAB9AMEN1 | |
| SCHEMBL8020408 | 0.82 | NPC1 (1.00) | SMARCA2SMARCA4NPC1RAB9AMEN1 | |
| SCHEMBL22125465 | 0.81 | L3MBTL1 (0.69) | SMARCA2SMARCA4NPC1RAB9AMEN1 | |
| SCHEMBL22154747 | 0.81 | SMARCA2 (0.68) | SMARCA2SMARCA4NPC1RAB9AMEN1 | |
| SCHEMBL9750118 | 0.80 | NPC1 (0.81) | SMARCA2SMARCA4NPC1RAB9AMEN1 | |
| SCHEMBL22125200 | 0.80 | SMARCA2 (1.00) | SMARCA2SMARCA4MEN1KMT2ALMNA | |
| SCHEMBL22125520 | 0.80 | SMARCA2 (0.76) | SMARCA2SMARCA4MEN1KMT2ALMNA | |
| SCHEMBL11044661 | 0.79 | POLB (0.68) | SMARCA2SMARCA4NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020126968-A2 | UREA DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | claimed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220016083-A1 | METHODS OF TREATING CANCERS | FOGHORN THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2020251969-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020126968-A2 | UREA DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016083-A1 | METHODS OF TREATING CANCERS | VHL, HNRNPH3, SMARCC2 | SMARCA2 11/4885SMARCA4 8/4885NPC1 2693/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | SMARCA2 4/4885SMARCA4 5/4885NPC1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.